Paper Details

  1. Home
  2. Paper Details

Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS.

Author: BakerAlva S, BrandtJason, DelCampoLourdes, FrangakisConstantine, LyketsosConstantine G, MilesQuincy, MunroCynthia, RabinsPeter V, SheppardJeannie-Marie E, SteeleCynthia D, SteinbergMartin

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

Sertraline is more effective than placebo in treating major depression in patients with Alzheimer disease. Depression reduction is associated with improved activities of daily living and reduced behavioral disturbance, but not improved cognition.
Paper Details　
Original Abstract of the Article :
CONTEXT: Major depression affects about 25% of the patients who have Alzheimer disease and has serious adverse consequences for patients and caregivers. Results of prior antidepressant treatment studies have produced contradictory findings and have not fully assessed the benefits of depression reduc...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/12860778

データ提供：米国国立医学図書館（NLM）

Treating Depression in Alzheimer's Disease: A Journey Through the Fog

Alzheimer's disease is a devastating condition, often accompanied by major depression, like a thick fog obscuring the mind and clouding the spirit. This study investigates the efficacy and safety of sertraline, an antidepressant medication, in treating depression in Alzheimer's patients. It's like a guide leading a lost traveler through a dense fog, seeking to restore clarity and brighten the path ahead.

A Light in the Fog

The research found that sertraline was superior to placebo in treating major depression in Alzheimer's patients, demonstrating a significant improvement in mood and overall well-being. It's like a beacon of hope shining through the fog, offering solace and relief to those suffering from depression. The study suggests that sertraline can be a valuable tool for alleviating depressive symptoms in this vulnerable population. It's like a desert caravan, finding a source of fresh water amidst the arid landscape, restoring vitality and providing renewed hope for the journey.

Navigating the Challenges of Alzheimer's Disease

These findings offer a glimmer of hope for patients with Alzheimer's disease and their families. It's like a desert oasis, offering respite and comfort in the face of adversity. The study underscores the importance of addressing depression in Alzheimer's patients, potentially leading to improved quality of life and reduced caregiver burden. It's like a camel caravan, ensuring the well-being of each member through careful planning and effective strategies.

Dr. Camel's Conclusion

This study demonstrates the effectiveness of sertraline in treating major depression in Alzheimer's patients, offering hope for individuals battling this challenging condition. It's like a desert expedition, armed with the right tools and knowledge to navigate the intricate and often treacherous terrain of Alzheimer's disease. This research underscores the importance of addressing depression in Alzheimer's patients, potentially leading to improved quality of life and reduced caregiver burden.

Date :
  1. Date Completed 2003-09-16
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

12860778

DOI: Digital Object Identifier

60/7/737

Related Literature

Article Analysis
・Effective treatment of depression
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.